Browsing Tag
NASDAQ: OCGN
1 post
How the GARDian3 trial could define the next commercial frontier in ophthalmic gene therapy
Discover how Ocugen, Inc.’s GARDian3 trial could redefine the commercial future of ophthalmic gene therapy and what investors should watch next.